Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KALV Stock Chart & Stats
$15.12
-$0.39(-4.51%)
At close: 4:00 PM EST
$15.12
-$0.39(-4.51%)
Day’s Range― - ―
52-Week Range$8.99 - $19.00
Previous CloseN/A
Volume49.40K
Average Volume (3M)1.31M
Market Cap
$783.97M
Enterprise Value$659.73M
Total Cash (Recent Filing)$309.16M
Total Debt (Recent Filing)$149.59M
Price to Earnings (P/E)―
Beta0.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding50,546,290
10 Day Avg. Volume860,242
30 Day Avg. Volume1,305,035
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)7.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.46
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue43.64
Enterprise Value/Gross Profit-254.23
Enterprise Value/Ebitda-2.77
Forecast
1Y Price Target
$34.88Price Target Upside130.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market AccessA commercialization agreement in major Latin American markets combined with expanding formulary coverage enhances the ability to broaden patient access and drive future sales.
Patient PersistenceA high share of prescription refills and repeat prescribers signals meaningful early patient persistence, which supports recurring revenue potential.
Physician AdoptionStrong early uptake among high-volume hereditary angioedema physicians indicates growing prescriber confidence and supports broader clinical adoption.
Bears Say
Adoption Breadth RiskUncertainty about whether prescribing will expand beyond core HAE physicians raises questions about the product's ability to reach a wider prescriber base.
Demand SustainabilityEarly sales driven mainly by refills and heavier-use patients suggests average refill frequency could decline as milder patients adopt, potentially slowing revenue growth.
Revenue VisibilityLimited disclosure of inventory levels and payer performance metrics restricts visibility into sustainable organic revenue and can create volatility in earnings expectations.
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $8.99 and its highest was $19.00 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is $783.97M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were KalVista Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 50,546,290 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in KALV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.88 (130.69% Upside)
$34.88 (130.69% Upside)
Blogger Sentiment
Neutral
KALV Sentiment 50%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.17%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Earnings Call
Q3 2025
0:00 / 0:00
KALV Stock 12 Month Forecast
Average Price Target
$34.88
▲(130.69% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---